Terminated PHASE3 INTERVENTIONAL 2-arm NCT00637468

EAGLE - Multicenter Study of the European Assessment Group for Lysis in the Eye (EAGLE)

Multizenterstudie Der European Assessment Group for Lysis in the Eye (EAGLE) Zur Behandlung Des Zentralarterienverschlusses (ZAV): Lysetherapie Versus Konservative Therapie

Sponsor: Boehringer Ingelheim

Conditions Fibrinolysis Hemodilution Retinal Artery Occlusion Stroke Visual Acuity

Interventions Acetylsalicylic acid Globe massage Intravenous injection of acetazolamide Intravenous injection of heparin Isovolaemic haemodilution Local intra-arterial fibrinolysis Topical use of beta-blocker

Updated 10 times since 2017 Last updated: Mar 17, 2008 Started: Sep 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to results of conditional power analysis performed at the first interim analysis and due to observed spectrum of adverse events.

Other terminated trials from Boehringer Ingelheim

See all terminations from Boehringer Ingelheim

A PHASE3 clinical study on Fibrinolysis and Hemodilution, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 10 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
University Hospital Freiburg

Data source: University Hospital Freiburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Augsburg, Germany , Bern, Switzerland , Bonn, Germany , Essen, Germany , Freiburg im Breisgau, Germany , Graz, Austria , Hamburg, Germany , Hanover, Germany , Homburg/Saar, Germany and 10 more locations